This podcast was developed and funded by AbbVie and is intended only for healthcare professionals experienced in the diagnosis and treatment of inflammatory bowel disease.
Please note that this podcast was developed in accordance with the UK and EU risankizumab SMPCs.
Click here for UK risankizumab 360 mg and 600 mg prescribing information.
Full Summary of Product Characteristics (SmPC) for Skyrizi (risankizumab) available here: EU – Spain – Germany – Brazil.
Risankizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
Please be aware that the label within your country may differ due to local regulations, and you should always consult your own label for prescribing and safety information about risankizumab.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]
In this podcast, listen to Laurent Peyrin-Biroulet’s insights into the latest data from the SEQUENCE trial, including implications for clinical practice.1,2
Listen as we explore:
- The objective and design of the SEQUENCE trial: A head-to-head, open-label Phase 3b trial comparing risankizumab and ustekinumab in patients with moderate-to-severe Crohn’s disease who previously failed anti‑TNF therapy1
- The primary endpoints in SEQUENCE were:1
- CDAI Clinical Remission at Week 24 (Non-inferiority of risankizumab vs. ustekinumab)*
- Endoscopic Remission at Week 48 (Superiority of risankizumab vs. ustekinumab)
- SEQUENCE 1-year open-label extension data presented at the 2025 European Crohn’s and Colitis Organisation (ECCO) Congress3
Speaker:
Laurent Peyrin-Biroulet1
1. President of the Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID), Paris, France
| Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected] |
References:
1. AbbVie Ltd. SKYRIZI [Summary of Product Characteristics]. Available at: https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf.; https://www.medicines.org.uk/emc/product/15011/smpc. Last accessed: 15 January 2026.
2. Peyrin-Biroulet L et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn’s disease. N Engl J Med. 2024;391(3):213-23.
3. Peyrin-Biroulet L et al. Efficacy and safety of risankizumab in patients with moderate to severe Crohn’s disease: results from the one-year SEQUENCE open-label long-term extension. J Crohns Colitis. 2025;19(3):DOI 10.1093/ecco-jcc/jjaf045. Corrected and republished from: J Crohns Colitis. 2025;19(Suppl 1):i1405-7.
* Noninferiority of risankizumab to ustekinumab was analysed among the first 50% of patients who completed the assessment at week 24 or withdrew from the trial
ALL-SKZG-250149
January 2026
